“Future work will use RECOVER’s biobank of cohort samples such as blood and spinal fluid, to develop more novel laboratory-based tests that help us better understand the pathophysiology of Long COVID,” said Kristine Erlandson, M.D., professor of medicine-infectious disease at the University of Colorado Anschutz Medical Campus, Aurora.

https://recovercovid.org/news/routine-lab-tes...long-covid
______________
Report is most likely a big factor on why NIH is now expanding RECOVER.

If there is NIH funding on-deck, his is great info & timing for a LL protocol design.